Shape Therapeutics and the Rett Syndrome Research Trust (RSRT) are teaming up to advance the development of SHP-401,…
Articles by Marisa Horak, MS
Taysha Gene Therapies is preparing for the potential commercial launch of TSHA-102, its experimental gene therapy for Rett…
Stimulating the vagus nerve — a large nerve that helps control unconscious bodily functions — partly normalized some measures of…
Abnormally high activity of the MECP2 gene can profoundly disrupt immature brain cells during early development, but appears to have…
Unravel Biosciences announced it has begun dosing in a proof-of-concept clinical trial evaluating its experimental therapy, RVL-001, in people…
In mouse models of Rett syndrome, disease-related changes in the MeCP2 protein were linked to widespread disruptions in histones,…
Different mutations that cause Rett syndrome can have divergent effects on brain cell activity, a study found. The findings…
Daybue Stix, a powder formulation of Daybue (trofinetide), is now widely available for eligible people with Rett syndrome…
Acadia Pharmaceuticals has hit a roadblock in its quest for European approval of trofinetide, the company’s oral therapy for…
A Phase 3 clinical trial testing the experimental gene therapy NGN-401 for Rett syndrome is underway and continuing to…